Effect of Adding Additional Elastic Band Resistance Training to Waltz Dance on Dyslipidemia in Middle-aged and Elderly Women: a Randomized Controlled Trial

Gdansk University of Physical Education and Sport60 enrolled

Overview

Brief Summary: This clinical trial aims to evaluate whether a 12-week multi-component exercise program (combining waltz, resistance training, and agility training) can improve the physical, psychological, and cognitive function of women aged 65 and under with dyslipidemia. Key research questions include: Does this intervention lower lipid levels (e.g., total cholesterol, triglycerides) and improve body composition (e.g., body fat percentage, lean muscle mass)? Compared to a non-exercise control group, does this intervention enhance cardiovascular health, balance, mental health, and cognitive function? Researchers will compare outcomes in the exercise intervention group and the non-exercise control group to assess the effectiveness of the program. Study Procedure: Participants will: attend supervised exercise classes three times a week for 12 weeks (approximately 90 minutes per class). The program includes: - Waltz training (basic steps and choreographed dance movements), - Resistance band exercises (targeting major muscle groups), - Agility and balance training modules. Pre- and post-intervention assessments will include: - Lipid analysis, - Body composition analysis, - Cardiovascular health and balance tests, - Standardized mental health and cognitive assessments.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Dyslipaemia

Eligibility

Sex: FEMALEMin age: 45 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Female, aged 45 to 65 years 2. Diagnosis of dyslipidemia defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, meeting at least one of the following: Total cholesterol ≥ 200 mg/dL Low-density lipoprotein cholesterol ≥ 130 mg/dL Triglycerides ≥ 150 mg/dL High-density lipoprotein cholesterol \< 50 mg/dL 3. Not taking lipid-lowering medications, or on a stable lipid-lowering regimen for at least 3 months prior to enrollment with no anticipated changes during the study period 4. Medically cleared to participate in moderate-intensity aerobic and resistance exercise according to American College of Sports Medicine (ACSM) guidelines 5. Able and willing to participate in a 12-week supervised exercise intervention 6. Provided written informed consent Exclusion Criteria 1. History of major cardiovascular events, including myocardial infarction, stroke, or unstable angina 2. Diagnosed diabetes with poor glycemic control 3. Serious metabolic or endocrine diseases known to affect lipid metabolism (e.g., uncontrolled thyroid disease) 4. Serious musculoskeletal, neurological, or orthopedic conditions that may limit safe participation in sports 5. Participated in a structured exercise program more than 2 times per week in the past 6 months 6. Current hormone replacement therapy or other medications known to significantly affect lipid metabolism 7. Cognitive impairment or psychiatric illness that may interfere with study participation or adherence 8. Any other medical condition that was deemed by the investigators to compromise the safety of the participants or the integrity of the data

Outcomes

Primary Outcomes

Total Cholesterol (TC) Level

Total cholesterol will be measured in fasting venous blood samples (12-hour fast) using an enzymatic colorimetric method with a clinical chemistry analyzer. The result will be reported in mg/dL. Total cholesterol refers to the overall amount of cholesterol in the blood, which includes LDL-C and HDL-C. High levels are associated with increased cardiovascular risk. Blood samples will be collected at baseline and at the end of the 12-week intervention.